Japanese pharma firm permits commercialisation of GI drug in India
Japan-based Takeda Pharmaceuticals entered into non-exclusive patent licensing agreements to commercialise Vonoprazan tablets with Sun Pharma and Cipla.
Japan-based Takeda Pharmaceuticals entered into non-exclusive patent licensing agreements to commercialise Vonoprazan tablets with Sun Pharma and Cipla.
The transaction marks the conclusion of a nearly 17-year effort to gain full control of the U.S.-listed generic drugmaker
Sun proposes to acquire outstanding shares of Taro’s at $43 apiece, up from $38 per share earlier
The price of the palbociclib treatment, which used to be at least ₹50,000 a month, will come down substantially.
The BSE Sensex and Nifty50 closed lower on Wednesday, led by selling in bank and realty stocks such as Bajaj Auto, Maruti, M&M, HDFC, Kotak Mahindra Bank, and SBI.
The Sensex and the Nifty are seen opening higher on Tuesday, following positive cues from Asian peers and firm trading in Nifty futures on the Singapore Exchange.
The top five gainers on the Sensex pack were Sun Pharma Industries, Tata Consultancy Services, NTPC, Wipro and Tech Mahindra.
The BSE Sensex and the NSE Nifty are seen opening higher, following firm cues from Asian peers and positive trends on the SGX Nifty futures.
Indian share market closed lower for the third straight session on Thursday, with BSE Sensex plunging 1,844 points during this period.
The BSE Sensex and the NSE Nifty are poised to start the week on the back foot, tracking mixed global cues and negative trading at SGX Nifty.